Interferons α and β in cancer: therapeutic opportunities from new insights

Nature Reviews Drug Discovery

Volumn 18, Issue 3, 2019, Pages 219-234

  Borden, Ernest C ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADU S 100; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AZACITIDINE; BETA INTERFERON; CANCER VACCINE; CYCLIC NUCLEOTIDE; CYCLOPHOSPHAMIDE; DECITABINE; DENDRITIC CELL VACCINE; DOXORUBICIN; FLAVONOID; FLUOROURACIL; IMIQUIMOD; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; RITUXIMAB; STING AGONIST; TOLL LIKE RECEPTOR 1 AGONIST; TOLL LIKE RECEPTOR 2 AGONIST; TOLL LIKE RECEPTOR 3 AGONIST; TOLL LIKE RECEPTOR 4 AGONIST; TOLL LIKE RECEPTOR 5 AGONIST; TOLL LIKE RECEPTOR 6 AGONIST; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 8 AGONIST; TOLL LIKE RECEPTOR 9 AGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; VADIMEZAN; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BASAL CELL CARCINOMA; BONE MARROW CELL; CANCER GENE THERAPY; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER MORTALITY; CANCER PROGNOSIS; CHEMORADIOTHERAPY; COLORECTAL CARCINOMA; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DENDRITIC CELL; DNA METHYLATION; DRUG EFFECT; DRUG POTENCY; GENE EXPRESSION; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; LYMPHOMA; MALIGNANT NEOPLASM; MELANOMA; METASTASIS; MORBIDITY; NATURAL KILLER CELL; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; ANIMAL; IMMUNOLOGY; NEOPLASM; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; INTERFERON-BETA; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 85060613743     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/s41573-018-0011-2     Document Type: Review

References (259)

1. Borden, E. C. et al. Interferons at age 50: past, current and future impact on biomedicine. Nat. Rev. Drug Discov. 6, 975–990 (2007). This review encompasses the underlying cellular effects of interferons for inhibition of cancer, viral infections and multiple sclerosis.
2. Gresser, I., Bourali, C., Levy, J. P., Fontaine-Brouty-Boye, D. & Thomas, M. T. Increased survival in mice inoculated with tumor cells and treated with interferon preparations. Proc. Natl Acad. Sci. USA 63, 51–57 (1969).
3. Borden, E. C. Interferons: rationale for clinical trials in neoplastic disease. Ann. Intern. Med. 91, 472–479 (1979).
4. Strander, H., Cantell, K., Carlstrom, G. & Jakobsson, P. A. Clinical & laboratory investigations on man: systemic administration of potent interferon to man. J. Natl Cancer Inst. 51, 733–742 (1973).
5. Gutterman, J. U. et al. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann. Intern. Med. 93, 399–406 (1980).
6. Borden, E. C. Progress toward therapeutic application of interferons, 1979–1983. Cancer 54, 2770–2776 (1984).
7. Quesada, J. R., Reuben, J., Manning, J. T., Hersh, E. M. & Gutterman, J. U. Alpha interferon for induction of remission in hairy-cell leukemia. N. Engl. J. Med. 310, 15–18 (1984).
8. Rai, K. R. et al. Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group B. Leukemia 9, 1116–1120 (1995).
9. Kantarjian, H. M. et al. Chronic myelogenous leukemia — progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J. Freireich Award Lecture. Clin. Cancer Res. 3, 2723–2733 (1997).
10. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Long-term follow-up of the Italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. Blood 92, 1541–1548 (1998).
11. Kirkwood, J. M. et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14, 7–17 (1996).
12. Ives, N. J. et al. Adjuvant interferon-alpha for the treatment of high-risk melanoma: an individual patient data meta-analysis. Eur. J. Cancer 82, 171–183 (2017). This article is an update on international trials assessing IFNα2 in reducing recurrence risk after resection of primary melanoma.
13. Rudick, R. A. & Goelz, S. E. Beta-interferon for multiple sclerosis. Exp. Cell Res. 317, 1301–1311 (2011).
14. Lin, F. C. & Young, H. A. Interferons: success in anti-viral immunotherapy. Cytokine Growth Factor Rev. 25, 369–376 (2014).
15. Hoffmann, H. H., Schneider, W. M. & Rice, C. M. Interferons and viruses: an evolutionary arms race of molecular interactions. Trends Immunol. 36, 124–138 (2015).
16. Borden, E. C. & Parkinson, D. A perspective on the clinical effectiveness and tolerance of interferon-alpha. Semin. Oncol. 25, 3–8 (1998). This review provides a perspective on the adverse effects of treatment with interferons.
17. Weber, J. S., Yang, J. C., Atkins, M. B. & Disis, M. L. Toxicities of immunotherapy for the practitioner. J. Clin. Oncol. 33, 2092–2099 (2015).
18. Masci, P. et al. Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha family. Clin. Pharmacol. Ther. 81, 354–361 (2007).
19. Kursunel, M. A. & Esendagli, G. The untold story of IFN-gamma in cancer biology. Cytokine Growth Factor Rev. 31, 73–81 (2016).
20. Lasfar, A., Gogas, H., Zloza, A., Kaufman, H. L. & Kirkwood, J. M. IFN-lambda cancer immunotherapy: new kid on the block. Immunotherapy 8, 877–888 (2016).
21. Chen, Q., Sun, L. & Chen, Z. J. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat. Immunol. 17, 1142–1149 (2016). This is a comprehensive review on the molecular and cellular aspects of the cGAS–STING axis.
22. Barber, G. N. STING: infection, inflammation and cancer. Nat. Rev. Immunol. 15, 760–770 (2015). This is an excellent review that complements the one above by adding more details on the pathophysiology of deregulation of the cGAS–STING pathway.
23. Woo, S. R. et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41, 830–842 (2014).
24. Wu, J. & Chen, Z. J. Innate immune sensing and signaling of cytosolic nucleic acids. Annu. Rev. Immunol. 32, 461–488 (2014).
25. Li, X. D. et al. Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects. Science 341, 1390–1394 (2013).
26. Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339, 786–791 (2013).
27. Wu, J. et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 339, 826–830 (2013).
28. Ikushima, H., Negishi, H. & Taniguchi, T. The IRF family transcription factors at the interface of innate and adaptive immune responses. Cold Spring Harb. Symp. Quant. Biol. 78, 105–116 (2013).
29. Liu, S. et al. Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. Science 347, aaa2630 (2015).
30. Ablasser, A. et al. Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP. Nature 503, 530–534 (2013).
31. Gray, E. E. et al. The AIM2-like receptors are dispensable for the interferon response to intracellular DNA. Immunity 45, 255–266 (2016).
32. Almine, J. F. et al. IFI16 and cGAS cooperate in the activation of STING during DNA sensing in human keratinocytes. Nat. Commun. 8, 14392 (2017).
33. Jonsson, K. L. et al. IFI16 is required for DNA sensing in human macrophages by promoting production and function of cGAMP. Nat. Commun. 8, 14391 (2017).
34. Zevini, A., Olagnier, D. & Hiscott, J. Crosstalk between cytoplasmic RIG-I and STING sensing pathways. Trends Immunol. 38, 194–205 (2017). This review discusses effects of stimulation of synthesis of interferons by both RNA and DNA.
35. McArthur, K. et al. BAK/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis. Science 359, eaao6447 (2018).
36. Yoneyama, M., Onomoto, K., Jogi, M., Akaboshi, T. & Fujita, T. Viral RNA detection by RIG-I-like receptors. Curr. Opin. Immunol. 32, 48–53 (2015).
37. Wu, Y., Wu, X., Wu, L., Wang, X. & Liu, Z. The anticancer functions of RIG-I-like receptors, RIG-I and MDA5, and their applications in cancer therapy. Transl Res. 190, 51–60 (2017).
38. Xu, X. X. et al. RIG-I: a multifunctional protein beyond a pattern recognition receptor. Protein Cell 9, 246–253 (2017).
39. Widau, R. C. et al. RIG-I-like receptor LGP2 protects tumor cells from ionizing radiation. Proc. Natl Acad. Sci. USA 111, E484–E491 (2014).
40. Klarquist, J. et al. STING-mediated DNA sensing promotes antitumor and autoimmune responses to dying cells. J. Immunol. 193, 6124–6134 (2014).
41. Corrales, L., McWhirter, S. M., Dubensky, Jr, T. W. & Gajewski, T. F. The host STING pathway at the interface of cancer and immunity. J. Clin. Invest. 126, 2404–2411 (2016). This review analyses the critical, immunomodulatory role of STING.
42. Larkin, B. et al. Cutting edge: activation of STING in T cells induces Type I IFN responses and cell death. J. Immunol. 199, 397–402 (2017).
43. Wang, H. et al. cGAS is essential for the antitumor effect of immune checkpoint blockade. Proc. Natl Acad. Sci. USA 114, 1637–1642 (2017).
44. Deng, L. et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41, 843–852 (2014).
45. Fu, J. et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci. Transl Med. 7, 283ra252 (2015).
46. Corrales, L. et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 11, 1018–1030 (2015).
47. Fuertes, M. B. et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J. Exp. Med. 208, 2005–2016 (2011).
48. Ohkuri, T. et al. STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Cancer Immunol. Res. 2, 1199–1208 (2014).
49. Spiotto, M., Fu, Y. X. & Weichselbaum, R. R. The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications. Sci. Immunol. 1, eaag1266 (2016). This is a review of augmentation of radiotherapeutic effects by type I interferons.
50. Song, S. et al. Decreased expression of STING predicts poor prognosis in patients with gastric cancer. Sci. Rep. 7, 39858 (2017).
51. Kato, K. et al. Structural and functional analyses of DNA-sensing and immune activation by human cGAS. PLOS ONE 8, e76983 (2013).
52. Baird, J. R. et al. Radiotherapy combined with novel STING-targeting oligonucleotides results in regression of established tumors. Cancer Res. 76, 50–61 (2016).
53. Luo, M. et al. A STING-activating nanovaccine for cancer immunotherapy. Nat. Nanotechnol. 12, 648–654 (2017).
54. Kimura, Y. et al. Novel chemical compound SINCRO with dual function in STING-type I interferon and tumor cell death pathways. Cancer Sci. 109, 2687–2696 (2018).
55. Leach, D. G. et al. STINGel: Controlled release of a cyclic dinucleotide for enhanced cancer immunotherapy. Biomaterials 163, 67–75 (2018).
56. Burnette, B. C. et al. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res. 71, 2488–2496 (2011).
57. Vanpouille-Box, C. et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat. Commun. 8, 15618 (2017).
58. Angioli, R. et al. In vitro potentiation of radiation cytotoxicity by recombinant interferons in cervical cancer cell lines. Cancer 71, 3717–3725 (1993).
59. Werner, L. R. et al. Transcriptional-mediated effects of radiation on the expression of immune susceptibility markers in melanoma. Radiother. Oncol. 124, 418–426 (2017).
60. Schiavoni, G. et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 71, 768–778 (2011).
61. Hannesdottir, L. et al. Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur. J. Immunol. 43, 2718–2729 (2013).
62. Sistigu, A. et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 20, 1301–1309 (2014).
63. Li, T. et al. Antitumor activity of cGAMP via stimulation of cGAS-cGAMP-STING-IRF3 mediated innate immune response. Sci. Rep. 6, 19049 (2016).
64. Demaria, O. et al. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proc. Natl Acad. Sci. USA 112, 15408–15413 (2015).
65. Harding, S. M. et al. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature 548, 466–470 (2017).
66. Benci, J. L. et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167, 1540–1554 (2016). This review details the influence of interferon pathways on immune checkpoint activation.
67. Garcia-Diaz, A. et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 19, 1189–1201 (2017).
68. Ito, T. et al. Differential regulation of human blood dendritic cell subsets by IFNs. J. Immunol. 166, 2961–2969 (2001).
69. Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J. & Kroemer, G. Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15, 405–414 (2015).
70. Alculumbre, S. et al. Plasmacytoid pre-dendritic cells (pDC): from molecular pathways to function and disease association. Semin. Cell Dev. Biol. 10.1016/j.semcdb.2018.02.014 (2018).
71. Banete, A., Seaver, K., Bakshi, D., Gee, K. & Basta, S. On taking the STING out of immune activation. J. Leukoc. Biol. 103, 1189–1195 (2018).
72. Mattei, F., Schiavoni, G., Belardelli, F. & Tough, D. F. IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation. J. Immunol. 167, 1179–1187 (2001).
73. Parlato, S. et al. Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood 98, 3022–3029 (2001).
74. Simmons, D. P. et al. Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing. J. Immunol. 188, 3116–3126 (2012).
75. Heise, R. et al. Interferon alpha signalling and its relevance for the upregulatory effect of transporter proteins associated with antigen processing (TAP) in patients with malignant melanoma. PLOS ONE 11, e0146325 (2016).
76. Diamond, M. S. et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208, 1989–2003 (2011).
77. Willemen, Y. et al. Engineering monocyte-derived dendritic cells to secrete interferon-alpha enhances their ability to promote adaptive and innate anti-tumor immune effector functions. Cancer Immunol. Immunother. 64, 831–842 (2015).
78. Zarling, J. M. et al. Enhancement of T cell cytotoxic responses by purified human fibroblast interferon. J. Immunol. 121, 2002–2004 (1978).
79. Brinkmann, V., Geiger, T., Alkan, S. & Heusser, C. H. Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells. J. Exp. Med. 178, 1655–1663 (1993).
80. Kolumam, G. A., Thomas, S., Thompson, L. J., Sprent, J. & Murali-Krishna, K. Type 1 interferons act directly on CD8 T cells to allow clonal expansion & memory formation in response to viral infection. J. Exp. Med. 202, 637–650 (2005).
81. Marshall, H. D., Prince, A. L., Berg, L. J. & Welsh, R. M. IFN-alpha beta and self-MHC divert CD8 T cells into a distinct differentiation pathway characterized by rapid acquisition of effector functions. J. Immunol. 185, 1419–1428 (2010).
82. Hervas-Stubbs, S. et al. CD8 T cell priming in the presence of IFN-alpha renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy. J. Immunol. 189, 3299–3310 (2012).
83. Gerner, M. Y., Heltemes-Harris, L. M., Fife, B. T. & Mescher, M. F. Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control. J. Immunol. 191, 1011–1015 (2013).
84. Harlin, H. et al. Chemokine expression in melanoma metastases associated with CD8+ T cell recruitment. Cancer Res. 69, 3077–3085 (2009).
85. Gajewski, T. F. et al. Cancer immunotherapy targets based on understanding the T cell-inflamed versus non-T cell-inflamed tumor microenvironment. Adv. Exp. Med. Biol. 1036, 19–31 (2017). This article analyses immunomodulation in the tumour microenvironment.
86. Gajewski, T. F. The next hurdle in cancer immunotherapy: overcoming the non-T cell-inflamed tumor microenvironment. Semin. Oncol. 42, 663–671 (2015).
87. Corrales, L., Matson, V., Flood, B., Spranger, S. & Gajewski, T. F. Innate immune signaling and regulation in cancer immunotherapy. Cell Res. 27, 96–108 (2017).
88. Le Bon, A. et al. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J. Immunol. 176, 2074–2078 (2006).
89. Izaguirre, A. et al. Comparative analysis of IRF and IFN-alpha expression in human plasmacytoid and monocyte-derived dendritic cells. J. Leukoc. Biol. 74, 1125–1138 (2003).
90. Kim, S. et al. Self-priming determines high type I IFN production by plasmacytoid dendritic cells. Eur. J. Immunol. 44, 807–818 (2014).
91. Tel, J. et al. Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities. Blood 120, 3936–3944 (2012).
92. Swiecki, M. & Colonna, M. The multifaceted biology of plasmacytoid dendritic cells. Nat. Rev. Immunol. 15, 471–485 (2015).
93. Kalb, M. L., Glaser, A., Stary, G., Koszik, F. & Stingl, G. TRAIL(+) human plasmacytoid dendritic cells kill tumor cells in vitro: mechanisms of imiquimod- and IFN-alpha-mediated antitumor reactivity. J. Immunol. 188, 1583–1591 (2012).
94. Wu, J. et al. TLR-activated plasmacytoid dendritic cells inhibit breast cancer cell growth in vitro and in vivo. Oncotarget 8, 11708–11718 (2017).
95. Butsch, R. et al. Intratumoral plasmacytoid dendritic cells associate with increased survival in patients with follicular lymphoma. Leuk. Lymphoma 52, 1230–1238 (2011).
96. Saulep-Easton, D. et al. Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemia. Leukemia 28, 2005–2015 (2014).
97. Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534, 396–401 (2016).
98. Kreutz, M. et al. Type I IFN-mediated synergistic activation of mouse and human DC subsets by TLR agonists. Eur. J. Immunol. 45, 2798–2809 (2015).
99. Shi, M., Chen, X., Ye, K., Yao, Y. & Li, Y. Application potential of toll-like receptors in cancer immunotherapy: systematic review. Medicine 95, e3951 (2016).
100. Mikulandra, M., Pavelic, J. & Glavan, T. M. Recent findings on the application of toll-like receptors agonists in cancer therapy. Curr. Med. Chem. 24, 2011–2032 (2017).
101. Ma, H. et al. Absence of Stat1 in donor CD4(+) T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice. J. Clin. Invest. 121, 2554–2569 (2011).
102. Sisirak, V. et al. Impaired IFN-alpha production by plasmacytoid dendritic cells favors regulatory T cell expansion that may contribute to breast cancer progression. Cancer Res. 72, 5188–5197 (2012).
103. Piconese, S., Pacella, I., Timperi, E. & Barnaba, V. Divergent effects of type-I interferons on regulatory T cells. Cytokine Growth Factor Rev. 26, 133–141 (2015).
104. Pace, L. et al. APC activation by IFN-alpha decreases regulatory T cell and enhances Th cell functions. J. Immunol. 184, 5969–5979 (2010).
105. Hashimoto, H. et al. Type I IFN gene delivery suppresses regulatory T cells within tumors. Cancer Gene Ther. 21, 532–541 (2014).
106. Anz, D. et al. Suppression of intratumoral CCL22 by type i interferon inhibits migration of regulatory T cells and blocks cancer progression. Cancer Res. 75, 4483–4493 (2015).
107. Edwards, B. S., Merritt, J. A., Fuhlbrigge, R. C. & Borden, E. C. Low doses of interferon alpha result in more effective clinical natural killer cell activation. J. Clin. Invest. 75, 1908–1913 (1985).
108. Muller, L., Aigner, P. & Stoiber, D. Type I Interferons and natural killer cell regulation in cancer. Front. Immunol. 8, 304 (2017).
109. Swann, J. B. et al. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J. Immunol. 178, 7540–7549 (2007).
110. Bidwell, B. N. et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat. Med. 18, 1224–1231 (2012).
111. Zhao, Y. et al. Overexpression of interferon regulatory factor 7 (IRF7) reduces bone metastasis of prostate cancer cells in mice. Oncol. Res. 25, 511–522 (2017).
112. Takashima, K. et al. STING in tumor and host cells cooperatively work for NK cell-mediated tumor growth retardation. Biochem. Biophys. Res. Commun. 478, 1764–1771 (2016).
113. Pylaeva, E., Lang, S. & Jablonska, J. The essential role of Type I interferons in differentiation and activation of tumor-associated neutrophils. Front. Immunol. 7, 629 (2016).
114. Andzinski, L. et al. Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human. Int. J. Cancer 138, 1982–1993 (2016).
115. Jablonska, J., Leschner, S., Westphal, K., Lienenklaus, S. & Weiss, S. Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J. Clin. Invest. 120, 1151–1164 (2010).
116. Wu, C. F. et al. The lack of type I interferon induces neutrophil-mediated pre-metastatic niche formation in the mouse lung. Int. J. Cancer 137, 837–847 (2015).
117. Zoglmeier, C. et al. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin. Cancer Res. 17, 1765–1775 (2011).
118. Chiappinelli, K. B. et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162, 974–986 (2015).
119. Saito, Y., Nakaoka, T. & Saito, H. A new molecular mechanism underlying the antitumor effect of DNA methylation inhibitors via an antiviral immune response. Adv. Protein Chem. Struct. Biol. 106, 227–242 (2017).
120. Leonova, K. I. et al. p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs. Proc. Natl Acad. Sci. USA 110, E89–E98 (2013).
121. Wrangle, J. et al. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget 4, 2067–2079 (2013).
122. Roulois, D. et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162, 961–973 (2015).
123. Stone, M. L. et al. Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proc. Natl Acad. Sci. USA 114, E10981–E10990 (2017).
124. Xia, T., Konno, H., Ahn, J. & Barber, G. N. Deregulation of STING signaling in colorectal carcinoma constrains DNA damage responses and correlates with tumorigenesis. Cell Rep. 14, 282–297 (2016).
125. Wang, L. X. et al. Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses. PLOS ONE 8, e62924 (2013).
126. Luo, N. et al. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat. Commun. 9, 248 (2018).
127. Chiappinelli, K. B., Zahnow, C. A., Ahuja, N. & Baylin, S. B. Combining epigenetic and immunotherapy to combat cancer. Cancer Res. 76, 1683–1689 (2016). This article discusses the potential of combining inhibition of genomic methylation and immunotherapy to augment effects of type I interferons.
128. Stark, G. R., Cheon, H. & Wang, Y. Responses to cytokines and interferons that depend upon JAKs and STATs. Cold Spring Harb. Perspect. Biol. 10, a028555 (2018). This review discusses the fundamental molecular effects of type I interferons on JAK–STAT-mediating signalling.
129. Stark, G. R. & Darnell, J. E. Jr. The JAK-STAT pathway at twenty. Immunity 36, 503–514 (2012).
130. Hertzog, P. J. & Williams, B. R. Fine tuning type I interferon responses. Cytokine Growth Factor Rev. 24, 217–225 (2013).
131. Cheon, H., Borden, E. C. & Stark, G. R. Interferons and their stimulated genes in the tumor microenvironment. Semin. Oncol. 41, 156–173 (2014). This is an overview of the molecular and cellular response modulated by interferons.
132. Shin, D. S. et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 7, 188–201 (2016).
133. Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819–829 (2016).
134. Battle, T. E., Lynch, R. A. & Frank, D. A. Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis. Cancer Res. 66, 3649–3657 (2006).
135. Fish, E. N. & Platanias, L. C. Interferon receptor signaling in malignancy: a network of cellular pathways defining biological outcomes. Mol. Cancer Res. 12, 1691–1703 (2014).
136. Rusinova, I. et al. Interferome v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res. 41, D1040–D1046 (2013).
137. Der, S. D., Zhou, A., Williams, B. R. & Silverman, R. H. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc. Natl Acad. Sci. USA 95, 15623–15628 (1998). This is a seminal paper that defines the spectrum of ISGs.
138. Schneider, W. M., Chevillotte, M. D. & Rice, C. M. Interferon-stimulated genes: a complex web of host defenses. Annu. Rev. Immunol. 32, 513–545 (2014).
139. Forster, S. C., Tate, M. D. & Hertzog, P. J. MicroRNA as Type I interferon-regulated transcripts and modulators of the innate immune response. Front. Immunol. 6, 334 (2015).
140. Ortiz, A. & Fuchs, S. Y. Anti-metastatic functions of type 1 interferons: Foundation for the adjuvant therapy of cancer. Cytokine 89, 4–11 (2017).
141. Gresser, I. & Belardelli, F. Endogenous type I interferons as a defense against tumors. Cytokine Growth Factor Rev. 13, 111–118 (2002).
142. Dunn, G. P. et al. A critical function for type I interferons in cancer immunoediting. Nat. Immunol. 6, 722–729 (2005).
143. Picaud, S., Bardot, B., De Maeyer, E. & Seif, I. Enhanced tumor development in mice lacking a functional type I interferon receptor. J. Interferon Cytokine Res. 22, 457–462 (2002).
144. Ascierto, M. L. et al. A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res. Treat. 131, 871–880 (2012).
145. Linsley, P. S., Speake, C., Whalen, E. & Chaussabel, D. Copy number loss of the interferon gene cluster in melanomas is linked to reduced T cell infiltrate and poor patient prognosis. PLOS ONE 9, e109760 (2014).
146. Chang, L. C. et al. IFNAR1 is a predictor for overall survival in colorectal cancer and its mRNA expression correlated with IRF7 but not TLR9. Medicine 93, e349 (2014).
147. Katlinski, K. V. et al. Inactivation of interferon receptor promotes the establishment of immune privileged tumor microenvironment. Cancer Cell 31, 194–207 (2017). This paper discusses the critical role of IFNAR in the tumour.
148. Chan, S. R. et al. STAT1-deficient mice spontaneously develop estrogen receptor alpha-positive luminal mammary carcinomas. Breast Cancer Res. 14, R16 (2012).
149. Gujam, F. J., McMillan, D. C. & Edwards, J. The relationship between total and phosphorylated STAT1 and STAT3 tumour cell expression, components of tumour microenvironment and survival in patients with invasive ductal breast cancer. Oncotarget 7, 77607–77621 (2016).
150. Schneckenleithner, C. et al. Putting the brakes on mammary tumorigenesis: loss of STAT1 predisposes to intraepithelial neoplasias. Oncotarget 2, 1043–1054 (2011).
151. Messina, N. L. et al. Modulation of antitumour immune responses by intratumoural Stat1 expression. Immunol. Cell Biol. 91, 556–567 (2013).
152. Yue, C. et al. Host STAT2/type I interferon axis controls tumor growth. Int. J. Cancer 136, 117–126 (2015).
153. Vestal, D. J. & Jeyaratnam, J. A. The guanylate-binding proteins: emerging insights into the biochemical properties & functions of this family of large interferon-induced guanosine triphosphatase. J. Interferon Cytokine Res. 31, 89–97 (2011).
154. Chawla-Sarkar, M. et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8, 237–249 (2003).
155. Chawla-Sarkar, M., Leaman, D. W. & Borden, E. C. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin. Cancer Res. 7, 1821–1831 (2001).
156. Chen, Q. et al. Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood 98, 2183–2192 (2001).
157. Cheriyath, V., Leaman, D. W. & Borden, E. C. Emerging roles of FAM14 family members (G1P3/ISG 6–16 and ISG12/IFI27) in innate immunity and cancer. J. Interferon Cytokine Res. 31, 173–181 (2011).
158. Reich, N. C. A death-promoting role for ISG54/IFIT2. J. Interferon Cytokine Res. 33, 199–205 (2013).
159. Mao, H. et al. Interferon-stimulated gene 15 induces cancer cell death by suppressing the NF-kappaB signaling pathway. Oncotarget 7, 70143–70151 (2016).
160. Gytz, H. et al. Apoptotic properties of the type 1 interferon induced family of human mitochondrial membrane ISG12 proteins. Biol. Cell 109, 94–112 (2017).
161. Zhou, M. J. et al. ISG15 inhibits cancer cell growth and promotes apoptosis. Int. J. Mol. Med. 39, 446–452 (2017).
162. Cheriyath, V. et al. G1P3, an interferon- and estrogen-induced survival protein contributes to hyperplasia, tamoxifen resistance and poor outcomes in breast cancer. Oncogene 31, 2222–2236 (2012).
163. Porritt, R. A. & Hertzog, P. J. Dynamic control of type I IFN signalling by an integrated network of negative regulators. Trends Immunol. 36, 150–160 (2015).
164. Arimoto, K. I., Miyauchi, S., Stoner, S. A., Fan, J. B. & Zhang, D. E. Negative regulation of type I IFN signaling. J. Leukoc. Biol. 103, 1099–1116 (2018). This review discusses the balance in interferon responses resulting from negative molecular regulation.
165. Weichselbaum, R. R. et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc. Natl Acad. Sci. USA 105, 18490–18495 (2008).
166. Khodarev, N. N., Roizman, B. & Weichselbaum, R. R. Molecular pathways: interferon/stat1 pathway: role in the tumor resistance to genotoxic stress and aggressive growth. Clin. Cancer Res. 18, 3015–3021 (2012).
167. Sung, P. S. et al. Roles of unphosphorylated ISGF3 in HCV infection and interferon responsiveness. Proc. Natl Acad. Sci. USA 112, 10443–10448 (2015).
168. Duarte, C. W. et al. Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner. PLOS ONE 7, e29653 (2012).
169. Kang, K., Robinson, G. W. & Hennighausen, L. Comprehensive meta-analysis of signal transducers and activators of transcription (STAT) genomic binding patterns discerns cell-specific cis-regulatory modules. BMC Genomics 14, 4 (2013).
170. Ng, K. W., Marshall, E. A., Bell, J. C. & Lam, W. L. cGAS-STING and cancer: dichotomous roles in tumor immunity and development. Trends Immunol. 39, 44–54 (2018).
171. Ahn, J. et al. Inflammation-driven carcinogenesis is mediated through STING. Nat. Commun. 5, 5166 (2014).
172. Bakhoum, S. F. et al. Chromosomal instability drives metastasis through a cytosolic DNA response. Nature 553, 467–472 (2018).
173. Yildirim, C. et al. Interferon-beta, a decisive factor in angiogenesis and arteriogenesis. J. Interferon Cytokine Res. 35, 411–420 (2015).
174. Sidky, Y. A. & Borden, E. C. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res. 47, 5155–5161 (1987).
175. Dvorak, H. F. & Gresser, I. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J. Natl Cancer Inst. 81, 497–502 (1989).
176. McCarty, M. F., Bielenberg, D., Donawho, C., Bucana, C. D. & Fidler, I. J. Evidence for the causal role of endogenous interferon-alpha/beta in the regulation of angiogenesis, tumorigenicity, and metastasis of cutaneous neoplasms. Clin. Exp. Metastasis 19, 609–615 (2002).
177. Spaapen, R. M. et al. Therapeutic activity of high-dose intratumoral IFN-beta requires direct effect on the tumor vasculature. J. Immunol. 193, 4254–4260 (2014).
178. Huang, S., Bucana, C. D., Van Arsdall, M. & Fidler, I. J. Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene 21, 2504–2512 (2002).
179. Gerber, S. A. & Pober, J. S. IFN-alpha induces transcription of hypoxia-inducible factor-1alpha to inhibit proliferation of human endothelial cells. J. Immunol. 181, 1052–1062 (2008).
180. Taylor, K. L. et al. Identification of interferon-beta-stimulated genes that inhibit angiogenesis in vitro. J. Interferon Cytokine Res. 28, 733–740 (2008).
181. Borden, E. C. et al. Gene regulatory and clinical effects of interferon beta in patients with metastatic melanoma: a phase II trial. J. Interferon Cytokine Res. 31, 433–440 (2011).
182. Cheng, X., Liu, Y., Chu, H. & Kao, H. Y. Promyelocytic leukemia protein (PML) regulates endothelial cell network formation and migration in response to tumor necrosis factor alpha (TNFalpha) and interferon alpha (IFNalpha). J. Biol. Chem. 287, 23356–23367 (2012).
183. Go, R. S. et al. ECOG phase II trial of graded-dose peginterferon alpha-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602). Clin. Cancer Res. 19, 6597–6604 (2013).
184. Takano, S., Ishikawa, E., Matsuda, M., Yamamoto, T. & Matsumura, A. Interferon-beta inhibits glioma angiogenesis through downregulation of vascular endothelial growth factor & upregulation of interferon inducible protein 10. Int. J. Oncol. 45, 1837–1846 (2014).
185. Hsu, K. S. et al. Dual regulation of Stat1 and Stat3 by the tumor suppressor protein PML contributes to interferon alpha-mediated inhibition of angiogenesis. J. Biol. Chem. 292, 10048–10060 (2017).
186. Guenzi, E. et al. The helical domain of GBP-1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines. EMBO J 20, 5568–5577 (2001).
187. Raffaella, R. et al. The interferon-inducible IFI16 gene inhibits tube morphogenesis and proliferation of primary, but not HPV16 E6/E7-immortalized human endothelial cells. Exp. Cell Res. 293, 331–345 (2004).
188. von Marschall, Z. et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J. Natl Cancer Inst. 95, 437–448 (2003).
189. Hiroi, M., Mori, K., Sakaeda, Y., Shimada, J. & Ohmori, Y. STAT1 represses hypoxia-inducible factor-1-mediated transcription. Biochem. Biophys. Res. Commun. 387, 806–810 (2009).
190. Legros, L. et al. Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib. Leuk. Res. 38, 662–665 (2014).
191. Dinney, C. P. et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res. 58, 808–814 (1998).
192. Singh, R. K., Gutman, M., Llansa, N. & Fidler, I. J. Interferon-beta prevents the upregulation of interleukin-8 expression in human melanoma cells. J. Interferon Cytokine Res. 16, 577–584 (1996).
193. Ezekowitz, R. A., Mulliken, J. B. & Folkman, J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N. Engl. J. Med. 326, 1456–1463 (1992).
194. Krown, S. E. AIDS-associated Kaposi’s sarcoma: is there still a role for interferon alfa? Cytokine Growth Factor Rev. 18, 395–402 (2007).
195. Rini, B. I. et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J. Clin. Oncol. 32, 752–759 (2014).
196. Pelham, J. M., Gray, J. D., Flannery, G. R., Pimm, M. V. & Baldwin, R. W. Interferon-alpha conjugation to human osteogenic sarcoma monoclonal antibody 791T/36. Cancer Immunol. Immunother. 15, 210–216 (1983).
197. Huang, T. H., Chintalacharuvu, K. R. & Morrison, S. L. Targeting IFN-alpha to B cell lymphoma by a tumor-specific antibody elicits potent antitumor activities. J. Immunol. 179, 6881–6888 (2007).
198. Rossi, E. A., Goldenberg, D. M., Cardillo, T. M., Stein, R. & Chang, C. H. CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B cell lymphomas. Blood 114, 3864–3871 (2009).
199. Dubrot, J. et al. Intratumoral injection of interferon-alpha and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy. Int. J. Cancer 128, 105–118 (2011).
200. Trinh, K. R. et al. Anti-CD20-interferon-beta fusion protein therapy of murine B cell lymphomas. J. Immunother. 36, 305–318 (2013).
201. Yang, X. et al. Targeting the tumor microenvironment with interferon-beta bridges innate and adaptive immune responses. Cancer Cell 25, 37–48 (2014).
202. Pogue, S. L. et al. Targeting attenuated interferon-alpha to myeloma cells with a CD38 antibody induces potent tumor regression with reduced off-target activity. PLOS ONE 11, e0162472 (2016).
203. Li, Z. et al. Anti-VEGFR2-interferon-alpha2 regulates the tumor microenvironment and exhibits potent antitumor efficacy against colorectal cancer. Oncoimmunology 6, e1290038 (2017).
204. Sondel, P. M. & Gillies, S. D. Current and potential uses of immunocytokines as cancer immunotherapy. Antibodies 1, 149–171 (2012).
205. Xuan, C., Steward, K. K., Timmerman, J. M. & Morrison, S. L. Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B cell lymphoma. Blood 115, 2864–2871 (2010).
206. Vega, G. G. et al. Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-alpha fusion protein: direct cytotoxicity and synergy with chemotherapy. Int. J. Oncol. 47, 1735–1748 (2015).
207. Greiner, J. W. et al. Evidence for the elevation of serum carcinoembryonic antigen and tumor-associated glycoprotein-72 levels in patients administered interferons. Cancer Res. 51, 4155–4163 (1991).
208. Ozzello, L., Derosa, C., Habif, D., Cantell, K. & Pestka, S. Up-regulation of a tumor-associated antigen (tag-72) by interferon-alpha and interferon-gamma in patients with cutaneous breast-cancer recurrences. Int. J. Oncol. 6, 985–991 (1995).
209. Sivaraman, S. et al. Effect of interferon-alpha on CD20 antigen expression of B cell chronic lymphocytic leukemia. Cytokines Cell. Mol. Ther. 6, 81–87 (2000).
210. Prowell, T. M., Theoret, M. R. & Pazdur, R. Seamless oncology—-drug development. N. Engl. J. Med. 374, 2001–2003 (2016).
211. Meyer, M. S. et al. Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis 31, 1597–1603 (2010).
212. Slattery, M. L., Lundgreen, A., Bondurant, K. L. & Wolff, R. K. Interferon-signaling pathway: associations with colon and rectal cancer risk and subsequent survival. Carcinogenesis 32, 1660–1667 (2011).
213. Lenci, R. E. et al. Influence of genetic variants in type I interferon genes on melanoma survival and therapy. PLOS ONE 7, e50692 (2012).
214. Lu, S. et al. Single nucleotide polymorphisms within interferon signaling pathway genes are associated with colorectal cancer susceptibility and survival. PLOS ONE 9, e111061 (2014).
215. Galon, J. et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J. Pathol. 232, 199–209 (2014).
216. Zainulabadeen, A., Yao, P. & Zare, H. Underexpression of specific interferon genes is associated with poor prognosis of melanoma. PLOS ONE 12, e0170025 (2017).
217. Doherty, M. R. et al. Interferon-beta represses cancer stem cell properties in triple-negative breast cancer. Proc. Natl Acad. Sci. USA 114, 13792–13797 (2017).
218. Piccaluga, P. P. et al. IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia. APMIS 125, 511–522 (2017).
219. Callari, M. et al. Subtype-dependent prognostic relevance of an interferon-induced pathway metagene in node-negative breast cancer. Mol. Oncol. 8, 1278–1289 (2014).
220. Godoy, P. et al. Interferon-inducible guanylate binding protein (GBP2) is associated with better prognosis in breast cancer and indicates an efficient T cell response. Breast Cancer 21, 491–499 (2014).
221. Parkes, E. E. et al. Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer. J. Natl Cancer Inst. 109, djw199 (2017).
222. Danish, H. H. et al. Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) as a prognostic marker for local control in T1-2 N0 breast cancer treated with breast-conserving surgery and radiation therapy (BCS + RT). Breast J. 19, 231–239 (2013).
223. Zhang, J. F. et al. High IFIT1 expression predicts improved clinical outcome, and IFIT1 along with MGMT more accurately predicts prognosis in newly diagnosed glioblastoma. Hum. Pathol. 52, 136–144 (2016).
224. Cohen, S. et al. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma. Gynecol. Oncol. 134, 591–598 (2014).
225. Ranoa, D. R. et al. Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs. Oncotarget 7, 26496–26515 (2016).
226. Legrier, M. E. et al. Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer. Br. J. Cancer 114, 177–187 (2016).
227. Kim, Y. A. et al. MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer. Breast Cancer Res. Treat. 156, 597–606 (2016).
228. Mushinski, J. F. et al. Inhibition of tumor cell motility by the interferon-inducible GTPase MxA. J. Biol. Chem. 284, 15206–15214 (2009).
229. Brown, S. G. et al. Interferon inducible antiviral MxA is inversely associated with prostate cancer and regulates cell cycle, invasion and Docetaxel induced apoptosis. Prostate 75, 266–279 (2015).
230. Margolis, S. R., Wilson, S. C. & Vance, R. E. Evolutionary origins of cGAS-STING signaling. Trends Immunol. 38, 733–743 (2017).
231. Mackenzie, K. J. et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature 548, 461–465 (2017).
232. Juergens, R. A. et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 1, 598–607 (2011).
233. Reu, F. J. et al. Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons. Cancer Res. 66, 2785–2793 (2006).
234. Reu, F. J. et al. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. J. Clin. Oncol. 24, 3771–3779 (2006).
235. Lucarini, V. et al. Combining type I interferons and 5-aza-2′-deoxycitidine to improve anti-tumor response against melanoma. J. Invest. Dermatol. 137, 159–169 (2017).
236. Lipnik, K. et al. Interferon gamma-induced human guanylate binding protein 1 inhibits mammary tumor growth in mice. Mol. Med. 16, 177–187 (2010).
237. Britzen-Laurent, N. et al. GBP-1 acts as a tumor suppressor in colorectal cancer cells. Carcinogenesis 34, 153–162 (2013).
238. Weinlander, K. et al. Guanylate binding protein-1 inhibits spreading and migration of endothelial cells through induction of integrin alpha4 expression. FASEB J. 22, 4168–4178 (2008).
239. Guenzi, E. et al. The guanylate binding protein-1 GTPase controls the invasive and angiogenic capability of endothelial cells through inhibition of MMP-1 expression. EMBO J. 22, 3772–3782 (2003).
240. Bleiziffer, O. et al. Guanylate-binding protein 1 expression from embryonal endothelial progenitor cells reduces blood vessel density and cellular apoptosis in an axially vascularised tissue-engineered construct. BMC Biotechnol. 12, 94 (2012).
241. Naschberger, E. et al. Angiostatic immune reaction in colorectal carcinoma: Impact on survival and perspectives for antiangiogenic therapy. Int. J. Cancer 123, 2120–2129 (2008).
242. Zoon, K. C. & Smith, M. E. The purification and characterization of interferons. Horiz. Biochem. Biophys. 6, 123–135 (1982).
243. Pestka, S. The human interferons—from protein purification and sequence to cloning and expression in bacteria: before, between, and beyond. Arch. Biochem. Biophys. 221, 1–37 (1983).
244. Gutterman, J. U. et al. Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann. Intern. Med. 96, 549–556 (1982).
245. Foote, J. B. et al. A STING agonist given with OX40 receptor and PD-L1 modulators primes immunity and reduces tumor growth in tolerized mice. Cancer Immunol. Res. 5, 468–479 (2017).
246. Weiss, J. M. et al. The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression. Oncoimmunology 6, e1346765 (2017).
247. Daei Farshchi Adli, A., Jahanban-Esfahlan, R., Seidi, K., Samandari-Rad, S. & Zarghami, N. An overview on Vadimezan (DMXAA): the vascular disrupting agent. Chem. Biol. Drug Des. 91, 996–1006 (2018).
248. Adamus, T. & Kortylewski, M. The revival of CpG oligonucleotide-based cancer immunotherapies. Contemp. Oncol. 22, 56–60 (2018).
249. Hou, J. et al. Hepatic RIG-I predicts survival and interferon-alpha therapeutic response in hepatocellular carcinoma. Cancer Cell 25, 49–63 (2014).
250. Engel, C. et al. RIG-I resists hypoxia-induced immunosuppression and dedifferentiation. Cancer Immunol. Res. 5, 455–467 (2017).
251. Crow, M. K. Type I interferon in the pathogenesis of lupus. J. Immunol. 192, 5459–5468 (2014).
252. Liu, Y. et al. Activated STING in a vascular and pulmonary syndrome. N. Engl. J. Med. 371, 507–518 (2014).
253. Yu, F. et al. IFITM1 promotes the metastasis of human colorectal cancer via CAV-1. Cancer Lett. 368, 135–143 (2015).
254. Ogony, J., Choi, H. J., Lui, A., Cristofanilli, M. & Lewis-Wambi, J. Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner. Breast Cancer Res. 18, 25 (2016).
255. Yang, Y. G. et al. Interferon-induced transmembrane protein 1-mediated EGFR/SOX2 signaling axis is essential for progression of non-small cell lung cancer. Int. J. Cancer 10.1002/ijc.31926 (2018).
256. Chen, R. H. et al. ISG15 predicts poor prognosis and promotes cancer stem cell phenotype in nasopharyngeal carcinoma. Oncotarget 7, 16910–16922 (2016).
257. D’Cunha, J. et al. Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc. Natl Acad. Sci. USA 93, 211–215 (1996).
258. Han, H. G., Moon, H. W. & Jeon, Y. J. ISG15 in cancer: beyond ubiquitin-like protein. Cancer Lett. 438, 52–62 (2018).
259. Machiraju, D. et al. STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-alpha. Melanoma Res. 28, 204–210 (2018).